DCPH vs. SNDX, FPRX, AGIO, XNCR, MCRB, ROIV, LNTH, RVMD, SMMT, and ELAN
Should you be buying Deciphera Pharmaceuticals stock or one of its competitors? The main competitors of Deciphera Pharmaceuticals include Syndax Pharmaceuticals (SNDX), Five Prime Therapeutics (FPRX), Agios Pharmaceuticals (AGIO), Xencor (XNCR), Seres Therapeutics (MCRB), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), Summit Therapeutics (SMMT), and Elanco Animal Health (ELAN). These companies are all part of the "medical" sector.
Syndax Pharmaceuticals (NASDAQ:SNDX) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment, community ranking and profitability.
Syndax Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
Syndax Pharmaceuticals received 52 more outperform votes than Deciphera Pharmaceuticals when rated by MarketBeat users. Likewise, 64.92% of users gave Syndax Pharmaceuticals an outperform vote while only 64.91% of users gave Deciphera Pharmaceuticals an outperform vote.
Deciphera Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 4 mentions for Syndax Pharmaceuticals and 0 mentions for Deciphera Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.95 beat Deciphera Pharmaceuticals' score of 0.36 indicating that Deciphera Pharmaceuticals is being referred to more favorably in the news media.
Syndax Pharmaceuticals presently has a consensus target price of $34.73, suggesting a potential upside of 41.80%. Deciphera Pharmaceuticals has a consensus target price of $24.17, suggesting a potential downside of 5.54%. Given Deciphera Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Syndax Pharmaceuticals is more favorable than Deciphera Pharmaceuticals.
71.0% of Deciphera Pharmaceuticals shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Deciphera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Syndax Pharmaceuticals has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -108.86%. Syndax Pharmaceuticals' return on equity of -52.42% beat Deciphera Pharmaceuticals' return on equity.
Summary
Syndax Pharmaceuticals beats Deciphera Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Deciphera Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Deciphera Pharmaceuticals Competitors List
Related Companies and Tools
